Europe Asthma Drugs Market

The Europe asthma drugs market is expected to reach US$ 9,636.62 million by 2028 from US$ 6,876.65 million in 2021; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028.

The growth of the market is attributed to the rising prevalence of asthma and the growing exposure to coarse particulate matters. However, the unmet medical needs hamper the market growth.

Asthma is a disorder in which psychological elements have played a significant role since the 20th century. Clinicians understand that emotional stress can trigger or exacerbate asthma and that a patient's mental health can impair asthma control by influencing symptom presentation and treatment adherence. As a result, there is a bi-directional link between asthma and psychological issues.

Asthmatics and asthma exacerbations are associated with periods of heightened emotionality. Depressive disorders are more common among people with asthma than in the general population, according to various prevalence estimates, some of which reach 40%. Patients with bipolar affective disorders tend to have a higher chance of acquiring IgE-mediated allergy diseases, such as asthma, than the general population. Anxiety disorders also have an elevated prevalence in asthma, affecting up to one-third of asthmatic children and adolescents and 24% of asthmatic adults.

Ambiguous disease criteria, inconsistencies in nomenclature, limited samples, and an emphasis on outpatient or inpatient population rather than the community affects the research on the frequency of psychological and mental disorders in asthmatics. The World Mental Health Survey addresses a few of these methodological issues by providing standardized data for 17 nations across the world. Compared to individuals without asthma, the pooled estimates of age- and sex-adjusted odds of mental disorders were 1.6 (95% CI=1.4, 1.8) for depressive disorders and 1.5 (95% CI=1.4,1.7) for anxiety disorders. There was also a link between asthma and alcohol use disorders (OR 1.7 (95% CI=1.4, 2.1) in this study.

Although the frequency of mental disorders and asthma varies substantially between nations, there was much less cross-sectional heterogeneity in their connection. Given that the countries represented varied greatly in terms of culture, healthcare organization, and socioeconomic development, this constancy is remarkable. It suggests that practitioners in any environment should be aware of the extensive overlap between asthma and psychological and mental illnesses.

Early psychosomatic models suggested that psychological discomfort played a role in varying asthma morbidity among asthma patients. However, emerging knowledge of pathophysiological pathways indicated that psychological variables might also play a role in the genesis of asthma. The disruption of critical biological systems such as the neuroendocrine stress response, cytokines, and neuropeptides is similar to asthma and serious depressive disorders. Additional evidence of a genetic relationship between atopic and depressed symptoms comes from twin-pair studies.

Because of the link between asthma and psychological issues, psychological therapies are occasionally employed to supplement pharmaceutical asthma care. Behavioral therapies, cognitive therapies, cognitive-behavioral therapies (CBT), relaxation techniques, psycho-dynamic psychotherapies, and counseling (both for the person and the family) have all been tried. Unlike pharmacological asthma treatments, there is still a lack of evidence regarding the effectiveness of psychosocial therapy in children and adults. This is expected to boost the need for asthma treatments in the coming years, driving the European asthma drugs market.

Europe Asthma Drugs Market Revenue and Forecast to 2028 (US$ Mn)

Get more information on this report Request Free Sample PDF

Europe Asthma Drugs Strategic Insights

Strategic insights for the Europe Asthma Drugs provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Asthma Drugs Report Scope

Europe Asthma Drugs Regional Insights

The geographic scope of the Europe Asthma Drugs refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Asthma Drugs Market Segmentation

The Europe asthma drugs market, by medication, is segmented into quick relief medications and long-term control medications. Based on route of administration, the market is segmented into inhaled, prefilled syringe/vials, and others.  Based on distribution channel, the Europe asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. By country, the market is segmented into the Germany, Spain, Italy, France, UK and Rest of Europe.

AstraZeneca; TEVA PHARMACEUTICAL INDUSTRIES LTD

;